Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on February 12, 2008
JNCI Journal of the National Cancer Institute 2008 100(4):282-284; doi:10.1093/jnci/djm311
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/4/282    most recent
djm311v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Patel, T. V.
Right arrow Articles by Humphreys, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, T. V.
Right arrow Articles by Humphreys, B. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib

Tejas V. Patel, Jeffrey A. Morgan, George D. Demetri, Suzanne George, Robert G. Maki, Michael Quigley, Benjamin D. Humphreys

Affiliations of authors: Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (TVP, BDH); Dana Farber Cancer Institute, Boston, MA (JAM, GDD, SG, MQ); Harvard Medical School, Boston, MA (TVP, JAM, GDD, SG, BDH); Memorial Sloan-Kettering Cancer Center, New York, NY (RGM); Weill Medical College of Cornell University, New York, NY (RGM)

Correspondence to: Benjamin D. Humphreys, MD, PhD, Harvard Institutes of Medicine Room 550, 4 Blackfan Circle, Boston, MA 02115 (e-mail: bhumphreys@partners.org).

The first 10% of the full text of this article appears below.

The oral multitargeted kinase inhibitors (MTKI) sunitinib (SU11248, Sutent; Pfizer, New York) and sorafenib (BAY 43-9006, Nexavar; Bayer Pharmaceuticals, West Haven, CT, and Onyx Pharmaceuticals, Emeryville, CA) are increasingly used to treat malignant solid tumors. These small-molecule agents inhibit signaling through receptor tyrosine kinases such as vascular endothelial growth factor (VEGF) receptor, platelet-derived growth factor receptor, and c-KIT, among others (1). In the kidney, . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. N. M. Overkleeft, R. Goldschmeding, F. van Reekum, E. E. Voest, and H. M. W. Verheul
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib
Ann. Onc., November 4, 2009; (2009) mdp472v1.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. D. Humphreys and M. B. Atkins
Rapid Development of Hypertension by Sorafenib: Toxicity or Target?
Clin. Cancer Res., October 1, 2009; 15(19): 5947 - 5949.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
N. Leung, N. A. Saucier, S. R. Zeldenrust, H. D. Gunderson, and L. D. Cornell
Acute renal failure after treatment with sunitinib in a patient with multiple myeloma
NDT Plus, August 1, 2009; 2(4): 292 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Bollee, N. Patey, G. Cazajous, C. Robert, J.-M. Goujon, F. Fakhouri, P. Bruneval, L.-H. Noel, and B. Knebelmann
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 682 - 685.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Katavetin, P. Katavetin, D. Nochy, C. Lefaucheur, G. Hill, B. Haraldsson, L. Barisoni, and S. E. Quaggin
VEGF Inhibition and Renal Thrombotic Microangiopathy
N. Engl. J. Med., July 10, 2008; 359(2): 205 - 207.
[Full Text] [PDF]